Natalia García-Sancha, Roberto Corchado-Cobos, Adrián Blanco-Gómez, Oriol Cunillera Puértolas, Mercè Marzo-Castillejo, Sonia Castillo-Lluva, Diego Alonso-López, Javier De Las Rivas, Julio Pozo, Alberto Orfao, Luis Valero-Juan, Carmen Patino-Alonso, David Perera, Ashok R Venkitaraman, Jian-Hua Mao, Hang Chang, Marina Mendiburu-Eliçabe, Patricia González-García, Eduardo Caleiras, Isabel Peset, María Begoña García Cenador, Francisco Javier García-Criado, Jesús Pérez-Losada
Post-pregnancy breast cancer often carries a poor prognosis, posing a major clinical challenge. The increasing trend of later-life pregnancies exacerbates this risk, highlighting the need for effective chemoprevention strategies. Current options, limited to selective estrogen receptor modulators, aromatase inhibitors, or surgical procedures, offer limited efficacy and considerable side effects. Here, we report that cabergoline, a dopaminergic agonist, reduces the risk of breast cancer post-pregnancy in a Brca1/P53 -deficient mouse model, with implications for human breast cancer prevention...
February 5, 2024: Research Square